// App-Quantinova.ai

DOP48 : Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

Researchers

Presenter

  • G DHaens

Principal Investigators

  • S Danese

  • M Davies

  • M Watanabe

  • T Hibi

Medical Centers

  • Academic Medical Center, Amsterdam, Netherlands

  • Humanitas Research Hospital, Radiology, Rozzano, Milan, Italy

  • Mitsubishi Tanabe Europe Ltd., London, UK

  • Tokyo Medical and Dental University, Gastroenterology, Tokyo, Japan

  • University Kitasato Hospital, Gastroenterology, Tokyo, Japan

Locations

  • Netherlands

  • Italy

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Sphingosine-1-phosphate

  • Twist-related protein 2

Drug/Treatment

  • MT1303

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

  • Prospective

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved